These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 12911597

  • 1. Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity.
    Hu H, Zhang W, Li N.
    J Thromb Haemost; 2003 Aug; 1(8):1805-12. PubMed ID: 12911597
    [Abstract] [Full Text] [Related]

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 3. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation.
    Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK.
    Blood; 1996 Feb 15; 87(4):1368-76. PubMed ID: 8608226
    [Abstract] [Full Text] [Related]

  • 4. Combined defect in membrane expression and activation of platelet GPIIb--IIIa complex without primary sequence abnormalities in myeloproliferative disease.
    Kaplan R, Gabbeta J, Sun L, Mao GF, Rao AK.
    Br J Haematol; 2000 Dec 15; 111(3):954-64. PubMed ID: 11122160
    [Abstract] [Full Text] [Related]

  • 5. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J.
    J Lab Clin Med; 2000 Mar 15; 135(3):247-55. PubMed ID: 10711863
    [Abstract] [Full Text] [Related]

  • 6. Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet-leukocyte interaction and thrombin generation.
    Li N, Wallén NH, Savi P, Hérault JP, Herbert JM.
    Blood Coagul Fibrinolysis; 1998 Sep 15; 9(6):507-15. PubMed ID: 9819001
    [Abstract] [Full Text] [Related]

  • 7. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY, Wu YC, Wu CC.
    Mol Pharmacol; 2006 Oct 15; 70(4):1380-9. PubMed ID: 16837624
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
    Naimushin YA, Mazurov AV.
    Biochemistry (Mosc); 2003 Feb 15; 68(2):209-16. PubMed ID: 12693968
    [Abstract] [Full Text] [Related]

  • 10. Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis.
    Brusilovskaya K, Simbrunner B, Lee S, Eichelberger B, Bauer D, Zinober K, Schwabl P, Mandorfer M, Panzer S, Reiberger T, Gremmel T.
    Platelets; 2022 Aug 18; 33(6):879-886. PubMed ID: 35294323
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Aug 18; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 12. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S.
    Atherosclerosis; 2014 Jan 18; 232(1):119-24. PubMed ID: 24401225
    [Abstract] [Full Text] [Related]

  • 13. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.
    J Cardiovasc Pharmacol; 1997 Aug 18; 30(2):261-72. PubMed ID: 9269956
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
    Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Steiner S, Panzer S.
    Eur J Clin Invest; 2013 Jul 18; 43(7):689-97. PubMed ID: 23611368
    [Abstract] [Full Text] [Related]

  • 17. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
    Ogawa T, Sugidachi A, Otsuguro K, Isobe T, Asai F.
    Biochem Pharmacol; 2002 May 15; 63(10):1911-8. PubMed ID: 12034376
    [Abstract] [Full Text] [Related]

  • 18. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 19. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets.
    Dorsam RT, Kim S, Jin J, Kunapuli SP.
    J Biol Chem; 2002 Dec 06; 277(49):47588-95. PubMed ID: 12297512
    [Abstract] [Full Text] [Related]

  • 20. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 06; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.